TABLE 1

Patient Demographics and Clinical Characteristics^*

	Trastuzumab protein dose (mg)
Characteristic	5	50	All patients
No. of patients	2	6	8
Age (y)
Median	60	54	56
Range	44–75	39–69	39–75
Prior anti-HER2 therapy
None		1	1
Adjuvant trastuzumab	1	2	3 (14, 18, 18)^†
Trastuzumab for metastasis	1	3	4 (4, 6, 14, 18)^†
Hormone receptor and HER2 status of recurrent disease
ER or PR positive	1	3	4
ER and PR negative	1	3	4
HER2
IHC3+	2	5	7
IHC2+/FISH positive		1	1
Sites of metastatic disease
Bone	2	4	6
Lymph nodes	2	5	7
Liver	2	2	4
Lung	1	1	2
Pleural effusion		1	1
Breast		2	2

↵* Entries are numbers of patients unless otherwise indicated.
↵† Months since last anti-HER2 therapy administration.
ER = estrogen receptor; PR = progesterone receptor; IHC = immunohistochemistry; FISH = fluorescence in situ hybridization.